Deans' stroke musings: Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, May 1, 2014

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

I suppose I shouldn't criticize all these smart people but I don't think much of their conclusions.
http://www.neurology.org/content/82/17/1556.full

Barbara S. Koppel, MD, FAAN,
John C.M. Brust, MD, FAAN,
Terry Fife, MD, FAAN,
Jeff Bronstein, MD, PhD,
Sarah Youssof, MD,
Gary Gronseth, MD, FAAN and
David Gloss, MD

+Show Affiliations

Correspondence to American Academy of Neurology: guidelines@aan.com

doi: 10.1212/WNL.0000000000000363 Neurology April 29, 2014 vol. 82 no. 17 1556-1563

Next Section

Abstract

Objective: To determine the efficacy of medical marijuana in several neurologic conditions.

Methods: We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles.

Results: Thirty-four studies met inclusion criteria; 8 were rated as Class I.

Conclusions: The following were studied in patients with MS: (1) Spasticity: oral cannabis extract (OCE) is effective, and nabiximols and tetrahydrocannabinol (THC) are probably effective, for reducing patient-centered measures; it is possible both OCE and THC are effective for reducing both patient-centered and objective measures at 1 year. (2) Central pain or painful spasms (including spasticity-related pain, excluding neuropathic pain): OCE is effective; THC and nabiximols are probably effective. (3) Urinary dysfunction: nabiximols is probably effective for reducing bladder voids/day; THC and OCE are probably ineffective for reducing bladder complaints. (4) Tremor: THC and OCE are probably ineffective; nabiximols is possibly ineffective. (5) Other neurologic conditions: OCE is probably ineffective for treating levodopa-induced dyskinesias in patients with Parkinson disease. Oral cannabinoids are of unknown efficacy in non–chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy. The risks and benefits of medical marijuana should be weighed carefully. Risk of serious adverse psychopathologic effects was nearly 1%. (I don't believe that, marijuana has never had any proven bad effects) Comparative effectiveness of medical marijuana vs other therapies is unknown for these indications.

Are you refuting these 13 studies?.